Shore Capital hails improved US biotech funding environment for hVIVO
12th Dec 2025 12:52
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Read moreHvivo client acquired by MSD in $9.2bn deal
27th Nov 2025 07:58
(Sharecast News) - Contract research organisation Hvivo congratulated its client Cidara Therapeutics on Thursday after the US biotech firm agreed to be acquired by Merck Sharp & Dohme in a deal worth around $9.2bn.
Read morehVivo reports positive results from its largest lab contract to date
30th Jun 2025 09:29
(Sharecast News) - hVivo reported positive topline results from a phase 2b field study conducted on behalf of Cidara Therapeutics on Monday, for which it provided participant recruitment, virology, and immunology laboratory services.
Read moreHvivo client cancels 'significant' HCT trial contract
30th May 2025 08:02
(Sharecast News) - Contract research organisation Hvivo has received notification that "a significant human challenge trial" contract has been cancelled, alongside a postponement and the cancellation of a smaller study.
Read morehVivo reports record full-year revenue, earnings
10th Apr 2025 09:09
(Sharecast News) - hVivo reported record revenue and EBITDA in its final results for 2024 on Thursday, supported by strong client demand for its human challenge trial services and the expansion of its operational capabilities, as it outlined plans to reach £100m in annual revenue by 2028.
Read morehVIVO acquires biological material storage specialist Cryostore
27th Feb 2025 15:13
(Sharecast News) - hVIVO announced the acquisition of Cryostore, a specialist provider of temperature-controlled storage solutions for biological and clinical materials, for up to £3.2m on Thursday.
Read moreHvivo signs £2m contract with new biopharma client
17th Feb 2025 11:45
(Sharecast News) - Contract research organisation Hvivo said on Monday that it has signed a £2.0m contract with a new biopharmaceutical client to complete the final stage of a characterisation study ahead of future hMPV human challenge trials.
Read morehVIVO reports positive results from Shionogi RSV trial
5th Feb 2025 10:19
(Sharecast News) - hVIVO reported positive results from a phase 2a respiratory syncytial virus (RSV) human challenge trial conducted on behalf of Shionogi on Wednesday.
Read morehVIVO signs human challenge trial contract with Inhalon Biopharma
3rd Feb 2025 07:48
(Sharecast News) - hVIVO announced on Monday that it has signed a contract with Inhalon Biopharma to conduct a human challenge trial assessing the efficacy of IN-002, an inhaled antiviral candidate for treating respiratory syncytial virus (RSV) infections.
Read moreHvivo acquires two clinical research units, FY revenues up 11.9pc
29th Jan 2025 09:15
(Sharecast News) - Contract research organisation Hvivo said on Wednesday that it has acquired two clinical research units from German outfit CRS Clinical Research Services.
Read morehVIVO signs LOI to conduct pivotal whooping cough study
27th Jan 2025 12:28
(Sharecast News) - hVIVO announced on Monday that it has signed a letter of intent with ILiAD Biotechnologies to conduct a pivotal phase three human challenge trial for ILiAD's lead whooping cough vaccine candidate, BPZE1.
Read morehVIVO secures largest standalone lab contract to date
21st Jan 2025 14:27
(Sharecast News) - hVIVO announced on Tuesday that it has secured its largest standalone laboratory contract to date, with its hLAB division signing a £2.7m deal with a US-based biotechnology client, bringing the total value of the project to £3.2m.
Read morehVIVO completes pilot study for hMPV challenge model
13th Jan 2025 14:40
(Sharecast News) - Contract research organisation and human challenge trial specialist hVIVO announced the successful completion of a pilot characterisation study for its human metapneumovirus (hMPV) challenge model on Monday.
Read moreHvivo strikes £11.5m RSV contract with existing client
10th Dec 2024 08:01
(Sharecast News) - Contract research organisation Hvivo has struck a £11.5m Respiratory Syncytial Virus contract with an "existing top-tier global pharmaceutical client".
Read morehVIVO upbeat on positive human challenge trial results with client
7th Oct 2024 10:21
(Sharecast News) - Specialist contract research organisation hVIVO announced positive results from a phase 2a human challenge trial (HCT) for Enanta Pharmaceuticals' RSV antiviral candidate, EDP-323, on Monday.
Read more